CN101679403B - 噁二唑衍生物配体及其作为亲代谢性谷氨酸受体增效剂842的用途 - Google Patents

噁二唑衍生物配体及其作为亲代谢性谷氨酸受体增效剂842的用途 Download PDF

Info

Publication number
CN101679403B
CN101679403B CN2008800191548A CN200880019154A CN101679403B CN 101679403 B CN101679403 B CN 101679403B CN 2008800191548 A CN2008800191548 A CN 2008800191548A CN 200880019154 A CN200880019154 A CN 200880019154A CN 101679403 B CN101679403 B CN 101679403B
Authority
CN
China
Prior art keywords
pain
disorders
neurological
disorder
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800191548A
Other languages
English (en)
Chinese (zh)
Other versions
CN101679403A (zh
Inventor
乔舒亚·克莱顿
伊恩·埃格尔
詹姆斯·恩普菲尔德
詹姆斯·福尔默
梅思文·艾萨克
马缚鹏
阿布德尔马利克·斯拉西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40093925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101679403(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101679403A publication Critical patent/CN101679403A/zh
Application granted granted Critical
Publication of CN101679403B publication Critical patent/CN101679403B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
CN2008800191548A 2007-06-07 2008-06-05 噁二唑衍生物配体及其作为亲代谢性谷氨酸受体增效剂842的用途 Expired - Fee Related CN101679403B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94255307P 2007-06-07 2007-06-07
US60/942,553 2007-06-07
PCT/SE2008/050666 WO2008150233A1 (en) 2007-06-07 2008-06-05 Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210486921.4A Division CN102977086B (zh) 2007-06-07 2008-06-05 噁二唑衍生物配体及其作为亲代谢性谷氨酸受体增效剂842的用途

Publications (2)

Publication Number Publication Date
CN101679403A CN101679403A (zh) 2010-03-24
CN101679403B true CN101679403B (zh) 2013-01-02

Family

ID=40093925

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008800191548A Expired - Fee Related CN101679403B (zh) 2007-06-07 2008-06-05 噁二唑衍生物配体及其作为亲代谢性谷氨酸受体增效剂842的用途
CN201210486921.4A Expired - Fee Related CN102977086B (zh) 2007-06-07 2008-06-05 噁二唑衍生物配体及其作为亲代谢性谷氨酸受体增效剂842的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210486921.4A Expired - Fee Related CN102977086B (zh) 2007-06-07 2008-06-05 噁二唑衍生物配体及其作为亲代谢性谷氨酸受体增效剂842的用途

Country Status (33)

Country Link
US (2) US8377940B2 (enExample)
EP (2) EP2444399B1 (enExample)
JP (2) JP5416696B2 (enExample)
KR (2) KR20150116907A (enExample)
CN (2) CN101679403B (enExample)
AR (1) AR066882A1 (enExample)
AU (1) AU2008260717B2 (enExample)
BR (1) BRPI0812889A2 (enExample)
CA (1) CA2690856C (enExample)
CL (1) CL2008001667A1 (enExample)
CO (1) CO6251287A2 (enExample)
CY (2) CY1113422T1 (enExample)
DK (2) DK2444399T3 (enExample)
EC (1) ECSP109856A (enExample)
ES (2) ES2393425T7 (enExample)
HR (2) HRP20120909T4 (enExample)
IL (1) IL202158A (enExample)
ME (1) ME01488B (enExample)
MX (1) MX2009013078A (enExample)
MY (1) MY158066A (enExample)
NZ (1) NZ582445A (enExample)
PE (1) PE20090328A1 (enExample)
PL (2) PL2167502T6 (enExample)
PT (2) PT2167502E (enExample)
RS (2) RS53845B1 (enExample)
RU (2) RU2470931C2 (enExample)
SA (1) SA08290344B1 (enExample)
SI (2) SI2167502T1 (enExample)
TW (1) TWI417100B (enExample)
UA (1) UA99129C2 (enExample)
UY (1) UY31124A1 (enExample)
WO (1) WO2008150233A1 (enExample)
ZA (1) ZA200908285B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
CA2698929C (en) 2007-09-14 2016-01-19 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
MX2010002538A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas.
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
ES2637794T3 (es) * 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
CN102131791B (zh) 2008-06-20 2014-12-24 阿斯利康(瑞典)有限公司 二苯并硫杂氮杂*衍生物及其用途
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
CA2744138C (en) 2008-11-28 2015-08-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
MX2012007992A (es) * 2010-01-07 2012-08-03 Astrazeneca Ab Proceso para producir modulador alosterico positivo receptor de glutamato metabotropico - 874.
US20130237548A1 (en) * 2010-04-30 2013-09-12 Astrazeneca Ab Injectable emulsion of sedative hypnotic agent
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN102180872B (zh) * 2011-04-01 2014-04-02 华中科技大学 [1,3,4]噁二唑类衍生物及其应用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
TW201713649A (zh) 2015-07-17 2017-04-16 武田藥品工業股份有限公司 雜環化合物
EP3327019A4 (en) * 2015-07-17 2019-04-03 Takeda Pharmaceutical Company Limited HETEROCYCLIC CONNECTION
US10406146B2 (en) 2015-08-25 2019-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
MX2022000693A (es) * 2019-07-18 2022-05-26 Abaxys Therapeutics Formulacion solida de un derivado de 1,2,4-oxadiazol.
GB2621323A (en) * 2022-08-03 2024-02-14 Sirgartan Holdings Ltd Treatments for obsessive compulsive disorder

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080397A2 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
WO2006020879A1 (en) * 2004-08-13 2006-02-23 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006123249A2 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
WO2006123255A2 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
WO2007021309A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
WO2007039439A1 (en) * 2005-09-27 2007-04-12 F.Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008803A (en) * 1932-04-18 1935-07-23 Stephan Engineering Corp Fuel atomizing and igniting means
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (fr) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. Derive de 3-methylenisoindolin-1-one
TW219935B (enExample) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
EP0887340A4 (en) * 1996-02-06 2000-03-29 Japan Tobacco Inc CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
WO1998054135A1 (en) 1997-05-30 1998-12-03 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
CA2311131A1 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
AU2001234175B2 (en) * 2000-02-29 2004-10-07 Mitsubishi Pharma Corporation Novel cyclic amide derivatives
SK1142003A3 (en) 2000-07-31 2003-06-03 Smithkline Beecham Plc Carboxamide compounds and their use as antagonists of a human 11CBY receptor
BR0208985A (pt) * 2001-04-19 2004-03-09 Eisai Co Ltd Derivados de 2-iminopirrolidina
WO2003016254A1 (en) 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
AU2003284669B2 (en) * 2002-11-26 2009-11-12 Maruishi Pharmaceutical Co., Ltd. Isoindoline derivative
US7507836B2 (en) 2003-03-26 2009-03-24 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) * 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
US20070135485A1 (en) 2003-10-22 2007-06-14 Gillig James R Novel mch receptor antagonists
US20080275062A1 (en) 2004-01-30 2008-11-06 David Harold Drewry Chemical Compounds
SI1731512T1 (sl) 2004-03-05 2015-01-30 Nissan Chemical Industries, Ltd. Z izoksazolinom substituirana benzamidna spojina in sredstvo za uravnavanje škodljivih organizmov
JPWO2005085214A1 (ja) 2004-03-05 2008-01-17 萬有製薬株式会社 ジアリール置換複素５員環誘導体
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
CA2584598A1 (en) 2004-10-25 2006-05-04 Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors
AU2006216917A1 (en) 2005-02-24 2006-08-31 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080397A2 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
WO2006020879A1 (en) * 2004-08-13 2006-02-23 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006123249A2 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
WO2006123255A2 (en) * 2005-05-18 2006-11-23 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
WO2007021309A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
WO2007039439A1 (en) * 2005-09-27 2007-04-12 F.Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists

Also Published As

Publication number Publication date
TW200911254A (en) 2009-03-16
AU2008260717B2 (en) 2012-01-19
CA2690856A1 (en) 2008-12-11
RS52526B2 (sr) 2018-06-29
SA08290344B1 (ar) 2011-10-03
BRPI0812889A2 (pt) 2017-05-23
CN101679403A (zh) 2010-03-24
EP2167502A1 (en) 2010-03-31
SI2444399T1 (sl) 2015-03-31
ES2393425T3 (es) 2012-12-21
US8377939B2 (en) 2013-02-19
ZA200908285B (en) 2010-08-25
ES2393425T7 (es) 2013-11-22
RS52526B (sr) 2013-04-30
RU2470931C2 (ru) 2012-12-27
TWI417100B (zh) 2013-12-01
US20080306077A1 (en) 2008-12-11
EP2444399A1 (en) 2012-04-25
CA2690856C (en) 2015-12-15
HK1166978A1 (en) 2012-11-16
JP2010529118A (ja) 2010-08-26
HK1142318A1 (en) 2010-12-03
PL2167502T3 (pl) 2013-01-31
SI2167502T1 (sl) 2012-12-31
CN102977086B (zh) 2015-04-01
KR20150116907A (ko) 2015-10-16
US20100267740A1 (en) 2010-10-21
CY1113422T1 (el) 2016-06-22
PL2167502T6 (pl) 2013-12-31
WO2008150233A1 (en) 2008-12-11
CY1116150T1 (el) 2017-02-08
PT2167502E (pt) 2012-11-26
EP2167502A4 (en) 2011-04-06
JP2014055164A (ja) 2014-03-27
MY158066A (en) 2016-08-30
UA99129C2 (ru) 2012-07-25
RS53845B1 (sr) 2015-08-31
RU2012141706A (ru) 2014-03-27
US8377940B2 (en) 2013-02-19
NZ582445A (en) 2012-03-30
KR20100017640A (ko) 2010-02-16
ECSP109856A (es) 2010-02-26
EP2444399B1 (en) 2014-11-26
DK2444399T3 (en) 2015-03-02
CO6251287A2 (es) 2011-02-21
CL2008001667A1 (es) 2009-03-06
AU2008260717A1 (en) 2008-12-11
IL202158A (en) 2015-11-30
PT2444399E (pt) 2015-03-04
EP2167502B1 (en) 2012-09-19
PE20090328A1 (es) 2009-04-24
AR066882A1 (es) 2009-09-16
ME01488B (me) 2014-04-20
DK2167502T3 (da) 2012-12-03
HRP20120909T4 (hr) 2013-11-08
HRP20120909T1 (en) 2012-12-31
EP2167502B3 (en) 2013-07-10
UY31124A1 (es) 2009-01-30
IL202158A0 (en) 2010-06-16
JP5416696B2 (ja) 2014-02-12
ES2531443T3 (es) 2015-03-16
MX2009013078A (es) 2010-01-15
JP5815644B2 (ja) 2015-11-17
HRP20150210T1 (en) 2015-06-05
RU2009147708A (ru) 2011-07-20
CN102977086A (zh) 2013-03-20
PL2444399T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
CN101679403B (zh) 噁二唑衍生物配体及其作为亲代谢性谷氨酸受体增效剂842的用途
US7799792B2 (en) Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841
CN101511802A (zh) 螺唑烷酮化合物及其作为代谢型谷氨酸受体增效剂的用途
CN101605792A (zh) 氮杂-异吲哚酮和它们作为亲代谢性谷氨酸受体增效剂-613的用途
RS53392B (sr) Derivati izoksazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora
AU2012258618A1 (en) Metabotropic glutamate receptors 5 modulators and methods of use thereof
US7868008B2 (en) Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) Metabotropic glutamate-receptor-potentiating isoindolones
HK1183480A (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842
HK1166978B (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor -842 potentiators
HK1142318B (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130102

Termination date: 20160605